Generic Name and Formulations:
Tropicamide 0.5%, 1%; oph soln; contains benzalkonium chloride.
Alcon Laboratories, Inc.
Indications for MYDRIACYL:
For mydriasis and cycloplegia for diagnostic procedures.
Adults and Children:
For refraction: instill 1–2 drops of 1% soln in the eye(s); repeated in 5 minutes. An additional drop may be instilled if patient is not seen within 20–30 minutes. For examination of fundus: instill 1–2 drops of 0.5% soln 15 or 20 minutes prior to exam. Lacrimal sac should be compressed by digital pressure for 2–3 minutes after instillation to reduce excessive systemic absorption.
Remove contact lenses before use. Pregnancy (Cat.C). Nursing mothers.
May interfere with antihypertensive action of carbachol, pilocarpine, or ophthalmic cholinesterase inhibitors.
Ocular (eg, stinging, blurred vision, photophobia, superficial punctuate keratitis, transient elevation of intraocular pressure), dry mouth, tachycardia, headache, allergic reactions, GI upset, pallor, CNS disturbances (esp. in children).
Soln 0.5%—15mL; 1%—3mL, 15mL
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Patterns of Non-Medical Prescription Opioid Use in Adolescents
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds